Comparison of long-term clinical outcome after successful implantation of Firebird sirolimus- and Taxus paclitaxel-eluting stents in Chinese population: Analysis of a large single center registry

Chinese Medical Journal

Volumn 123, Issue 7, 2010, Pages 810-815

  Dou, Ke Fei ^a   Xu, Bo ^a   Yang, Yue Jin ^a   Chen, Ji Lin ^a   Qiao, Shu Bin ^a   Wang, Yang ^a   Li, Jian Jun ^a   Qin, Xue Wen ^a   Yao, Min ^a   Liu, Hai Bo ^a   Wu, Yong Jian ^a   Chen, Jue ^a   Yuan, Jin Qing ^a   You, Shi Jie ^a   Li, Wei ^a   Gao, Run Lin ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Firebird sirolimus eluting stent; Taxus paclitaxel eluting stent; Treatment outcome

Indexed keywords

PACLITAXEL; RAPAMYCIN;

ADULT; ARTICLE; CHINESE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; HEART INFARCTION; HUMAN; IMPLANT REGISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; REVASCULARIZATION; RISK ASSESSMENT; RISK REDUCTION; THROMBOSIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; SIROLIMUS; TREATMENT OUTCOME;

EID: 77950910232     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.07.009     Document Type: Article

References (25)

1. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomized clinical trials of durg-eluting stents. Lancet 2004; 364: 583-591.
2. Eisenberg MJ, Konnyu KJ. Review of randomized clinical trials of drug-eluting stents for the prevention of in-stent restenosis. Am J Cardiol 2006; 8: 375-382.
3. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, et al. Outcomes associated with durg-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007; 370: 937-948.
4. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen JD, van Es JA, et al. On behalf of the Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344-2351.
5. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non- randomized control group. Stat Med 1998; 17: 2265-2281.
6. Marzocchi A, Saia F, Piovaccari G, Manari A, Aurier E, Benassi A, et al. Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL Multicenter Registry. Circulation 2007; 115: 3181-3188.
7. Garg P, Normand SL, Silbaugh TS, Wolf RE, Zelevinsky K, Lovett A, et al. Drug-eluting of bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts data analysis center registry. Circulation 2008; 118: 2277-2285.
8. Mauri L, Silbaugh TS, wolf RE, Zelevinsky K, Lovett A, Zhou Z, et al. Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts. Circulation 2008; 118: 1817-1827.
9. Katritsis DG, Korovesis S, Karabinos I, Giazitzoglou E, Theodorou S, Karvouni E, et al. Sirolimus- versus paclitaxel- eluting stents: a comparison of two consecutive series in routine clinical practice. J Intervent Cardiol 2006; 19: 31-37.
10. Schömig A, Dibra A, Windecker S, Mehilli J, Suárez de Lezo J, Kaiser C, et al. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 1373-1380.
11. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkings KD, Morice MC, et al. Safety and efficacy of sirolimus and paclitaxel eluting coronary stents. N Engl J Med 2007; 356: 998-1008.
12. Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, et al. Sirolimus- vs. paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 2006; 295: 895-904.
13. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, et al. Late clinical events after clopidegrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006; 48: 2584-2591.
14. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, et al. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus. JACC 2008; 52: 727-733.
15. Mehilli J, Dibra A, Kastrati A, Pache J, Dirschinger J, Schomig A. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J 2006; 27: 260-266.
16. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting stents in routine clinical practice. Data from a large two-institutional cohort study. Lancet 2007; 369: 667-678.
17. Rogers CD. Drug-eluting stent: a comparison between CYPHER and TAXUS. Rev Cardiovasc Med 2005; 6: S13-S21.
18. Windecker S, Remondino A, Eberli FR, Juni P, Raber L, Wenaweser P, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005; 353: 653-662.
19. Levin AD, Vukmirovic N, Hwang CW, Edelman ER. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc Natl Acad Sci USA 2004; 101: 9463-9467.
20. Schwartz SM. Smooth muscle migration in atherosclerosis and restenosis. J Clin Invest 1997; 100: S87-S89.
21. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first generation drug-eluting stents: a cause for concern. Circulation 2007 115: 1440-1455.
22. Trabattoni D, Fabbiocchi F, Montorsi P, Ravagnani P, Galli S, Teruzzi G, et al. Stent thrombosis after sirolimus- and paclitaxel-eluting stent implantation in daily clinical practice: analysis of a single center registry. Catheter Cardiovasc Interv 2007; 70: 415-421.
23. Gervasoni JE Jr, Hindenburg AA, Vezeridis MP, Schulze S, Wanebo HJ, Mehta S. An effective in vitro antitumor response against human pancreatic carcinoma with paclitaxel and daunorubicin by induction of both necrosis and apoptosis. Anticancer Res 2004; 24: 2617-2626.
24. Mancini D, Pinney S, Burkhoff D, LaManca J, Itescu S, Burke E, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003; 108: 48-53.
25. Camenzind E. Treatment of in-stent restenosis, back to the future? N Engl J Med 2006; 255: 2149-2151.